Claims for Patent: 10,004,745
✉ Email this page to a colleague
Summary for Patent: 10,004,745
| Title: | Use of inhibitors of Bruton\'S tyrosine kinase (Btk) |
| Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
| Inventor(s): | Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 15/066,600 |
| Patent Claims: | 1. A method for treating follicular lymphoma in an individual who has failed at least one prior therapy for follicular lymphoma, comprising: administering to the individual
once per day about 560 mg of an oral dose of a compound having the structure: ##STR00049##
2. The method of claim 1, wherein the follicular lymphoma is follicular small cleaved cell lymphoma, follicular mixed small cleaved and large cell lymphoma, or follicular large cell lymphoma. 3. The method of claim 1, wherein, following administration of the compound, the individual achieves a stable disease, a partial response, or a complete response. 4. The method of claim 1, wherein, following administration of the compound, the individual achieves a partial response or a complete response. 5. The method of claim 1, wherein, following administration of the compound, the individual achieves a complete response. 6. The method of claim 1, wherein, following administration of the compound, the individual does not experience a progressive disease. 7. The method of claim 1, wherein the prior therapy comprised administration of rituximab. |
Details for Patent 10,004,745
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Try for Free | 2030-06-03 |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | June 22, 2017 | ⤷ Try for Free | 2030-06-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 2 of 2 entries
